117mSn-HTC (117mSn-Tin Colloid, Synovetin OA) is developed and was brought on the market as a radiosynovectomy treatment for veterinary applications. The drug is a colloidal form of 117mSn particles in a restricted size range that does not escape from a joint when injected as arthritis therapeutic (i.e., radiosynoviorthesis or RSO). The drug was introduced on the (veterinary) market in June 2018. The drug is under further development for human application.
117mSn-HTC is a nuclear veterinary drug, available for application in dogs, cats, horses, camels and dromedaries. The molecule is not available for human use, but it is now under Phase I human RSO clinical trials in Canada.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.